ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.74 and traded as low as $1.73. ESSA Pharma shares last traded at $1.77, with a volume of 131,678 shares trading hands.
Analyst Ratings Changes
EPIX has been the subject of several recent research reports. Oppenheimer lowered ESSA Pharma from an "outperform" rating to a "market perform" rating in a report on Monday, November 4th. Piper Sandler lowered shares of ESSA Pharma from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $15.00 to $2.00 in a research report on Monday, November 4th. Finally, Jefferies Financial Group downgraded shares of ESSA Pharma from a "buy" rating to a "hold" rating in a report on Monday, November 4th.
Read Our Latest Stock Report on ESSA Pharma
ESSA Pharma Trading Down 0.6 %
The business has a fifty day moving average of $1.74 and a 200-day moving average of $4.12. The firm has a market cap of $78.12 million, a PE ratio of -2.84 and a beta of 1.61.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last announced its quarterly earnings results on Tuesday, December 17th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. On average, equities analysts forecast that ESSA Pharma Inc. will post -0.7 EPS for the current year.
Insider Buying and Selling at ESSA Pharma
In other news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the business's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $1.53, for a total transaction of $12,055,761.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 14.70% of the company's stock.
Institutional Investors Weigh In On ESSA Pharma
Several hedge funds have recently bought and sold shares of EPIX. RTW Investments LP lifted its stake in shares of ESSA Pharma by 41.9% in the 3rd quarter. RTW Investments LP now owns 3,261,496 shares of the company's stock valued at $19,765,000 after acquiring an additional 962,834 shares during the last quarter. Parkman Healthcare Partners LLC raised its stake in shares of ESSA Pharma by 37.2% during the third quarter. Parkman Healthcare Partners LLC now owns 345,902 shares of the company's stock valued at $2,096,000 after acquiring an additional 93,830 shares during the last quarter. Finally, FNY Investment Advisers LLC purchased a new stake in shares of ESSA Pharma during the fourth quarter worth about $44,000. 75.12% of the stock is currently owned by institutional investors.
ESSA Pharma Company Profile
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Read More
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
